Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20180628
    Release date: 18 February 2019

    Promoter – Financial Intermediary

    ALFASIGMA SPA

    Location

    Description

    The project will finance Alfasigma's R&D investments to be made in the period 2019-2022. In particular, financing will cover the promoter's research activities (clinical and regulatory development) for the development of innovative drugs in the areas of gastroenterology, vascular medicine and rheumatology.

    Objectives

    By co-investing in this project, the EIB contributes to making medical treatments for what the healthcare system considers high priority diseases, whilst also fostering the generation of European scientific knowledge and acumen.

    Sector(s)

    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 100 million

    Total cost (Approximate amount)

    EUR 251 million

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Procurement

    Alfasigma is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Status

    Signed - 13/09/2019

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Italy Services